Neuberger Berman Group
KRYS icon

Neuberger Berman Group’s Krystal Biotech KRYS Stock Holding History

Neuberger Berman Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.55M Buy
33,084
+32,051
+3,103% +$8.53M 0.01% 853
2025
Q4 		$255K Buy
+1,033
New +$217K ﹤0.01% 1874
2021
Q4 		– Sell
-45,246
Closed -$2.35M – 1927
2021
Q3 		$2.35M Buy
45,246
+583
+1% +$34.5K ﹤0.01% 1128
2021
Q2 		$3.03M Buy
44,663
+603
+1% +$42.1K ﹤0.01% 1085
2021
Q1 		$3.39M Sell
44,060
-6,940
-14% -$505K ﹤0.01% 1040
2020
Q4 		$3.06M Hold
51,000
– – ﹤0.01% 1028
2020
Q3 		$2.2M Buy
51,000
+8,000
+19% +$347K ﹤0.01% 1047
2020
Q2 		$1.78M Buy
43,000
+18,000
+72% +$866K ﹤0.01% 1025
2020
Q1 		$1.08M Sell
25,000
-15,600
-38% -$816K ﹤0.01% 1081
2019
Q4 		$2.25M Hold
40,600
– – ﹤0.01% 1009
2019
Q3 		$1.41M Buy
40,600
+24,800
+157% +$1.11M ﹤0.01% 1078
2019
Q2 		$636K Buy
15,800
+6,300
+66% +$206K ﹤0.01% 1244
2019
Q1 		$313K Buy
+9,500
New +$224K ﹤0.01% 1356

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group's KRYS Position: Q1 2026 in Review

Neuberger Berman Group increased its Krystal Biotech (KRYS) stake by 3,103% in Q1 2026, buying an estimated $8.53M and bringing the position to 33,084 shares worth $8.55M. The position accounts for 0.01% of the portfolio, ranked #853.

Neuberger Berman Group first reported a position in KRYS in Q1 2019 and has held it in 13 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Neuberger Berman Group held 33,084 shares of Krystal Biotech worth $8.55M as of Q1 2026.
  • Neuberger Berman Group bought 32,051 Krystal Biotech shares in Q1 2026, an estimated $8.53M.
  • Krystal Biotech made up 0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #853 holding.
  • Neuberger Berman Group first reported a position in Krystal Biotech in Q1 2019 and has held it in 13 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.